Oncolytics Biotech Inc.
ONCY
$0.9888
-$0.0212-2.10%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -14.78% | -8.17% | -9.91% | -41.69% | -4.58% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -28.75% | -24.65% | -7.34% | -11.89% | 8.59% |
Operating Income | 28.75% | 24.65% | 7.34% | 11.89% | -8.59% |
Income Before Tax | 16.03% | 8.88% | -98.91% | 5.49% | 4.92% |
Income Tax Expenses | -11.53% | -- | -48.10% | 69.23% | 98.29% |
Earnings from Continuing Operations | 15.97% | 8.88% | -97.31% | 5.44% | 4.27% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 15.97% | 8.88% | -97.31% | 5.44% | 4.27% |
EBIT | 28.75% | 24.65% | 7.34% | 11.89% | -8.59% |
EBITDA | 28.81% | 24.69% | 7.25% | 12.05% | -8.53% |
EPS Basic | 29.70% | 18.97% | -87.79% | 14.34% | 18.86% |
Normalized Basic EPS | 29.77% | 19.06% | -89.30% | 14.35% | 19.48% |
EPS Diluted | 29.70% | 18.97% | -87.79% | 14.34% | 18.86% |
Normalized Diluted EPS | 29.77% | 19.06% | -89.30% | 14.35% | 19.48% |
Average Basic Shares Outstanding | 19.59% | 12.48% | 5.11% | 10.33% | 18.03% |
Average Diluted Shares Outstanding | 19.59% | 12.48% | 5.11% | 10.33% | 18.03% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |